Table 2 FDA approvals of MTA or immuno-oncology combinations in adult solid tumors between January 2006 and June 2016 [20]
From: Approaches to modernize the combination drug development paradigm
Year of approval | Tumor type | Combinationa | Biomarker(s) |
|---|---|---|---|
2016 | RCC | Lenvatinib + everolimusb | |
2016 | Breast | Palbociclib + fulvestrantb | HR positive, HER2-negative |
2015 | Squamous NSCLC | Necitumumab + cisplatin/gemcitabine | |
2015 | Melanoma | Cobimetinib + vemurafenibb | BRAF V600 mutation |
2015 | Melanoma | Nivolumab + Ipilimumabb | |
2015 | CRC | Ramucirumab + FOLFIRI | |
2015 | Breast | Palbociclib + letrozoleb | HR positive, HER2-negative |
2014 | NSCLC | Ramucirumab + docetaxel | |
2014 | Ovarian, fallopian tube, primary peritoneal | Bevacizumab + paclitaxel, liposomal doxorubicin or topotecan | |
2014 | Cervix | Bevacizumab + paclitaxel/cisplatin or paclitaxel/topotecan | |
2014 | Gastric/GE junction | Ramucirumab + paclitaxel | |
2014 | Melanoma | Trametinib + dabrafenibb | BRAF V600 mutation |
2012 | CRC | Ziv-aflibercept + FOLFIRI | |
2012 | Breast | Everolimus + exemestaneb | HR positive, HER2-negative |
2012 | CRC | Cetuximab + FOLFIRI | KRAS wild type |
2012 | Breast | Pertuzumab + trastuzumab and docetaxelb | HER2 amplified/protein overexpression |
2011 | SCCHN | Cetuximab + platinum/fluoropyrimidine | |
2010 | Gastric/GE junction | Trastuzumab + cisplatin/fluoropyrimidine | HER2 protein overexpression |
2010 | Breast | Lapatinib + letrozoleb | HER2 amplified/protein overexpression and HR positive |
2009 | RCC | Bevacizumab + interferon-α | |
2008 | Breast | Bevacizumab + paclitaxel | HER2 negative |
2007 | Breast | Lapatinib + capecitabine | HER2 amplified/protein overexpression |
2006 | Breast | Trastuzumab + AC–T | HER2 amplified/protein overexpression |
2006 | NSCLC | Bevacizumab + platinum-based chemotherapy | |
2006 | CRC | Bevacizumab + fluoropyrimidine-based chemotherapy | |
2006 | SCCHN | Cetuximab + radiation |